Skip to main content

Table 3 Multivariable logistic regression for associations between CD4, cART and other risk factors with anal HPV infection among HIV-positive males in Taizhou, China

From: Increased CD4+ T cell count is associated with lower anal human papillomavirus prevalence among HIV-positive male cohort in Taizhou, China: a cross-sectional study

 

Any HPV

Any HR-HPV

Any LR-HPV

aOR (95% CI)

P-value

aOR (95% CI)

P-value

aOR (95% CI)

P-value

Age(years)

      

 18–24

1.00

 

1.00

 

1.00

 

 25–34

1.41 (0.53, 3.76)

0.497

1.25 (0.46, 3.38)

0.662

4.29 (1.19, 15.42)

0.026

 35–44

1.04 (0.36, 2.98)

0.945

0.92 (0.32, 2.69)

0.878

2.38 (0.61, 9.28)

0.212

 45–54

2.02 (0.66, 6.13)

0.215

1.80 (0.58, 5.59)

0.311

4.21 (1.02, 17.40)

0.047

 55–82

1.41 (0.43, 4.61)

0.567

1.24 (0.37, 4.21)

0.725

4.20 (0.91, 19.31)

0.065

Level of education

      

 Illiterate or primary school

1.00

 

1.00

 

1.00

 

 Middle school

2.01 (1.10, 3.66)

0.023

2.84 (1.49, 5.40)

0.002

3.82 (1.71, 8.52)

0.001

 High school

1.46 (0.71, 2.99)

0.301

2.11 (0.99, 4.48)

0.052

1.81 (0.71, 4.60)

0.214

 College or above

1.18 (0.52, 2.70)

0.692

1.55 (0.66, 3.64)

0.315

1.26 (0.44, 3.63)

0.670

Marital status

      

 Never married

1.00

 

1.00

 

1.00

 

 Currently married

0.55 (0.31, 0.98)

0.042

0.47 (0.26, 0.86)

0.014

0.65 (0.33, 1.28)

0.211

 Widowed/divorced

0.67 (0.32, 1.39)

0.282

0.86 (0.41, 1.81)

0.688

0.50 (0.20, 1.22)

0.125

Smoking amount (packyear)

1.00 (0.99, 1.00)

0.507

1.00 (0.99, 1.00)

0.514

1.00 (0.99, 1.00)

0.451

Alcohol consumption

      

 Drank≤once/month

1.00

 

1.00

 

1.00

 

 Drank > once/month

0.75 (0.46, 1.22)

0.244

0.53 (0.31, 0.89)

0.016

0.92 (0.50, 1.70)

0.801

Sexual orientation

      

 Hetero-sexual

1.00

 

1.00

 

1.00

 

 Homo-sexual

2.12 (1.32, 3.41)

0.002

2.41 (1.48, 3.92)

 < 0.001

3.54 (1.97, 6.35)

 < 0.001

 Bi-sexual or uncertain

2.47 (1.25, 4.90)

0.010

1.98 (0.99, 3.97)

0.053

2.29 (1.00, 5.24)

0.049

Self-reported history of STIs

      

 No

1.00

 

1.00

 

1.00

 

 Yes

1.22 (0.78, 1.92)

0.378

1.29 (0.81, 2.05)

0.287

1.49 (0.88, 2.52)

0.140

Multiple sex partnersa

      

 No

1.00

 

1.00

 

1.00

 

 Yes

0.84 (0.37, 1.92)

0.684

0.95 (0.40, 2.24)

0.903

0.35 (0.14, 0.89)

0.028

Condom use c

      

 Yes

1.00

 

1.00

 

1.00

 

 No

0.17 (0.02, 1.60)

0.122

0.09 (0.01, 0.86)

0.037

0.24 (0.04, 1.42)

0.116

Baseline CD4+ T (cells/µL)

      

  < 200

1.00

 

1.00

 

1.00

 

 200–349

1.47 (0.88, 2.45)

0.141

1.40 (0.83, 2.37)

0.211

0.92 (0.50, 1.69)

0.792

 350–499

1.13 (0.55, 2.32)

0.730

0.88 (0.42, 1.85)

0.736

1.33 (0.57, 3.10)

0.509

  ≥ 500

2.02 (0.82, 4.97)

0.126

1.09 (0.43, 2.76)

0.849

0.91 (0.31, 2.73)

0.872

Current CD4+ T (cells/µL)

      

  < 200

1.00

 

1.00

 

1.00

 

 200–349

0.58 (0.28, 1.22)

0.153

0.43 (0.20, 0.91)

0.028

0.91 (0.38, 2.15)

0.829

 350–499

0.28 (0.13, 0.64)

0.002

0.28 (0.12,0.64)

0.003

0.43 (0.16, 1.12)

0.085

  ≥ 500

0.26 (0.11, 0.60)

0.002

0.26 (0.11, 0.62)

0.002

0.54 (0.21, 1.43)

0.215

cART

      

 EFV + 3TC + TDF

1.00

 

1.00

 

1.00

 

 EFV + 3TC + AZT

0.87 (0.51, 1.48)

0.607

1.00 (0.58, 1.73)

0.999

1.02 (0.55, 1.88)

0.958

 NVP + 3TC + AZT

0.72 (0.40, 1.33)

0.299

0.47 (0.25, 0.90)

0.023

0.40 (0.18, 0.88)

0.023

 Others combined

0.71 (0.35, 1.47)

0.361

0.67 (0.32, 1.42)

0.295

1.05 (0.45, 2.46)

0.906

Duration of cART (years)

      

  < 2

1.00

 

1.00

 

1.00

 

 2– < 5

0.96 (0.59, 1.57)

0.869

0.78 (0.47, 1.30)

0.336

0.74 (0.41, 1.33)

0.310

  ≥ 5

0.74 (0.40, 1.38)

0.343

0.63 (0.33, 1.21)

0.166

0.93 (0.44, 1.98)

0.852

  1. aOR adjusted odds ratio, adjusted for all variables listed in the same column
  2. cART combined antiretroviral therapy (741 participants were under cART), EFV Efavirenz, 3TC Lamivudine, TDF Tenofovir, AZT Zidovudine, NVP Nevirapine
  3. aLife-time multiple sex partners; condom use in the last 6 months
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us